CagriSema 2.4/2.4 mg versus CagriSema 1.0/1.0 mg in adults with type 2 diabetes: a dose-comparison systematic review and meta-analysis of randomized controlled trials
CagriSema 2.4/2.4 mg provided additional weight loss smaller than the MID, no clear HbA1c benefit, and more gastrointestinal adverse events than 1.0/1.0 mg, supporting individualized dose selection.
Abstract
Background: Once-weekly cagrilintide-semaglutide (CagriSema) has been evaluated at two maintenance doses, 2.4/2.4 mg and 1.0/1.0 mg, in type 2 diabetes (T2DM), but they have not been directly compared. We compared their efficacy and safety. Methods: We searched PubMed, Embase, and Cochrane CENTRAL for randomized controlled trials (RCTs) comparing both doses. Contrasts derived from arm-level estimates were pooled using random-effects models. Primary outcomes were interpreted against prespecified minimally important differences (MIDs) of 3 percentage points (pp) for body weight and 0.3 pp (3.3 mmol/mol) for glycated hemoglobin (HbA1c). Results: Three trials (1,506 participants) were included. CagriSema 2.4/2.4 mg produced a greater reduction in body weight (mean difference [MD] -2.07 pp; 95% confidence interval [CI] -2.91 to -1.24), with the entire CI below the MID, and higher proportions achieving reductions of [≥]10% (64.9% vs. 55.1%) and [≥]15% (41.9% vs. 30.9%). The difference in HbA1c was not statistically significant (MD -0.16 pp [-1.7 mmol/mol]; 95% CI -0.43 to 0.10 [-4.7 to 1.1 mmol/mol]). The higher dose increased gastrointestinal disorders (64.8% vs. 53.2%; risk ratio 1.22; 95% CI 1.12 to 1.32), without differences in serious adverse events or adverse events leading to treatment discontinuation. Certainty of evidence was high for body weight and moderate for HbA1c. Conclusions: CagriSema 2.4/2.4 mg provided additional weight loss smaller than the MID, no clear HbA1c benefit, and more gastrointestinal adverse events than 1.0/1.0 mg, supporting individualized dose selection.
CagriSema provides substantial glycaemic and body-weight benefits versus placebo and is more evident for body-weight reduction, while comparative gastrointestinal tolerability and discontinuation risk remain uncertain.
C. S. Kow, A. F. Zaihan, D. Ramachandram et al.· Diabetes, obesity and metabo...· 0 citations
CagriSema produces clinically meaningful additional weight loss and modest improvements in surrogate cardiometabolic measures compared with semaglutide 2.4 mg alone, at the cost of more frequent injection-site reactions and, at most, modestly more frequent gastrointestinal events.
Zehra Khatoon Rasool, Rajvi K. Shah, Ansharah E. Zinnia Batool et al.· Frontiers in Endocrinology· 0 citations
INTRODUCTION
We explored the impact of the Sociodemographic Index (SDI) on the efficacy/safety of tofacitinib and adalimumab in patients with rheumatoid arthritis (RA).
METHODS
This post hoc analysis used data from phase 2/3/3b/4 studies of patients with RA receiving tofacitinib 5 or 10 mg twice daily (BID), adalimum...
Grace Wright, E. Mysler, Kevin D. Roberts et al.· Rheumatology and Therapy· 0 citations
Abstract Aims To evaluate whether dapagliflozin attenuates early cardiac functional and biomarker changes during anthracycline-based chemotherapy. Materials & Methods In this randomized, double-blind, placebo-controlled phase II trial, 94 adults were assigned 1:1 to dapagliflozin 10 mg once daily or placebo for 4 month...
H. Saeed, N. Mohammed Ali, R. Othman· Future Science OA· 0 citations
IMPORTANCE
Cagrilintide-semaglutide (CagriSema) is a fixed-dose combination of the amylin receptor agonist cagrilintide and the glucagon-like peptide-1 receptor agonist semaglutide administered subcutaneously once weekly. CagriSema has demonstrated significant weight reduction and improved glycemic control in participa...
M. Cavender, Ania M. Jastreboff, Alice Y. Y. Cheng et al.· American Heart Journal· 0 citations